– UK, Nottinghamshire – Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT platform technology, announces the appointment of Julian Hirst to the Company’s Board as Non-Executive Director.
Julian is a seasoned finance executive with experience across a broad range of corporate finance transactions including equity private placements, initial public offerings, public debt and equity issues, mergers and acquisitions, trade sales, strategic partnerships and restructurings. Julian is currently Corporate Finance Director of Immunocore Limited and also runs a Single Family Office which represents a high profile hedge fund manager. Prior to this, Julian held senior positions at several of the leading global investment banks including Panmure Gordon, UBS Warburg, Morgan Stanley and Lehman Brothers.
Geoffrey Hamilton-Fairley, CEO of Oncimmune commented: “At the time of the IPO the we made clear our intention to recruit an additional independent non-executive director and we are very pleased to have attracted such a top level candidate to the Board. Julian has an impressive track record and the significant sector expertise he brings with him will provide us with important guidance as we continue to deliver on the strategy outlined during our IPO to build on our EarlyCDT platform through expansion into new markets and indications.”
Commenting on his appointment, Julian Hirst said: “I’m very pleased to join the Board of Oncimmune at this exciting time in its development. The ability of Oncimmune’s autoantibody tests to detect cancer up to four years earlier than other methods is highly compelling and I look forward to working with the Board and management as the Company fulfils its potential.”
About Oncimmune
Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT-Lung, was launched in 2012, as a CLIA test in the USA and since then over 145,000 commercial tests have been sold. EarlyCDT-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT tests for liver and ovarian cancer are in development.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
